Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $36.49M |
| Gross Profit (TTM) | $-88.86M |
| EBITDA | $-119.94M |
| Operating Margin | -1167.00% |
| Return on Equity | -52.30% |
| Return on Assets | -27.10% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $2.88 |
| Price-to-Book | 1.30 |
| Price-to-Sales (TTM) | 6.11 |
| EV/Revenue | 3.279 |
| EV/EBITDA | 2.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -59.90% |
| Shares Outstanding | $60.42M |
| Float | $44.22M |
| % Insiders | 15.13% |
| % Institutions | 56.44% |
Volatility is currently expanding
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul.
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year.
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau - LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD).
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational tau silencing gene therapy for Alzheimer's disease (AD), in a late-breaking presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting in Boston, May 11-15, 2026.
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.
